

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



AEBSF hydrochloride

Cat. No.: HY-12821 CAS No.: 30827-99-7 Molecular Formula: $C_8H_{11}ClFNO_2S$

Molecular Weight: 239.69

Target: Thrombin; Influenza Virus; Ser/Thr Protease Pathway: Metabolic Enzyme/Protease; Anti-infection 4°C, sealed storage, away from moisture Storage:

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (417.21 mM; Need ultrasonic)

 $H_2O : \ge 100 \text{ mg/mL} (417.21 \text{ mM})$

* "≥" means soluble, but saturation unknown.

| Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|------------------------------|-------------------------------|-----------|------------|------------|
| | 1 mM | 4.1721 mL | 20.8603 mL | 41.7206 mL |
| | 5 mM | 0.8344 mL | 4.1721 mL | 8.3441 mL |
| | 10 mM | 0.4172 mL | 2.0860 mL | 4.1721 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS

Solubility: 100 mg/mL (417.21 mM); Clear solution; Need ultrasonic

2. Add each solvent one by one: Saline

Solubility: 100 mg/mL (417.21 mM); Clear solution; Need ultrasonic

3. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (8.68 mM); Clear solution

4. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (8.68 mM); Clear solution

5. Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (8.68 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

AEBSF hydrochloride is an irreversible inhibitor of serine proteases, such as chymotrypsin, kallikrein, plasmin, thrombin, and trypsin.

In Vitro

AEBSF inhibits the constitutive production of A β by directly inhibiting β -secretase in five different human cell lines, both neural and nonneural^[1].

AEBSF, as a serine protease inhibitor, inhibits the lysis of leukemic cells by human macrophages without inhibiting macrophage secretion of TNF- α and IL-1 β ^[2].

AEBSF also disturbs the growth of blastocysts on endometrial cells and inhibit the adhesion of HeLa cells on HUVECs by altering the protein secretion pattern^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AEBSF (76.8 mg/kg daily, i.p.) results in prolongation of the survival of mice that have been given a lethal T. gondii infection ^[3].?AEBSF also reduces airway response and underlying inflammation in cockroach allergen-induced murine model^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay [4]

The HeLa cells suspended in RPMI-1640 media containing 10% FCS are plated into each well of a 96-well microplate (5×10^3 cells/200 μ L/well). After incubation for 24 h at 37°C, cells are treated with different doses of AEBSF (0, 25, 50, 100 μ g/mL) for 48 h. Then, 20 μ L fresh 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-diphenytetrazoliumromide (MTT) reagent (5μ g/ μ L) is added into each well, and cells are cultured at 37°C in 5% CO $_2$ for another 4 h. The media are discarded carefully, and 150 μ L DMSO is added. Absorbance is read on a microplate reader at dual wavelengths of 540 and 620 nm.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration [3]

Mice injected with 2.5×10³ parasites are randomLy assigned to one of the treatment groups according to the treatment given: without drugs (control group), vehicle alone (vehicle control group), pyrimethamine alone at different doses, LY311727 alone at different doses, AEBSF alone at different doses or AEBSF 76.8 mg/kg plus pyrimethamine 10 mg/kg. Each treatment group consists of 10 animals. Treatment is initiated 24 h after parasite inoculation and is continued for seven consecutive days. Mouse survival is monitored daily and continued in live mice until 15 days post-infection. All experiments are performed three times and the data shown represent the cumulative results.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Autophagy. 2021 Jul;17(7):1592-1613.
- J Pharm Anal. 2023 May 15.
- J Virol. 2021 Dec 1;JVI0110321.
- Int J Oncol. 2019 Jul;55(1):331-339.
- Arch Biochem Biophys. 2020 Jul 30;688:108402.

See more customer validations on $\underline{www.MedChemExpress.com}$

REFERENCES

- $[1]. \ Citron\ M,\ et\ al.\ Inhibition\ of\ amyloid\ beta-protein\ production\ in\ neural\ cells\ by\ the\ serine\ protease\ inhibitor\ AEBSF.\ Neuron.\ 1996\ Jul; 17(1):171-9$
- [2]. Nakabo Y, et al. Lysis of leukemic cells by human macrophages: inhibition by 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), a serine protease inhibitor. J Leukoc Biol. 1996 Sep;60(3):328-36.
- [3]. Buitrago-Rey R, et al. Evaluation of two inhibitors of invasion: LY311727 [3-(3-acetamide-1-benzyl-2-ethyl-indolyl-5-oxy)propane phosphonic acid] and AEBSF [4-(2-aminoethyl)-benzenesulphonyl fluoride] in acute murine toxoplasmosis. J Antimicrob Chemother.

| 4]. Jiang YH, et al. Serine prote vith cell adhesion in vitro. Con | | | chloride (AEBSF) inhibits the rat embryo | o implantation in vivo and interferes |
|---|-------------------|---|--|---------------------------------------|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | dical applications. For research us | |
| | Tel: 609-228-6898 | Fax: 609-228-5909 Deer Park Dr, Suite Q, Monmo | E-mail: tech@MedChemExpres | s.com |
| | Address, 1 | beer rank bi, suite Q, Monino | atti sanction, No 00052, OSA | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

Page 3 of 3 www.MedChemExpress.com